Psychomotor retardation and externally oriented thinking in major depression

Código QR

Psychomotor retardation and externally oriented thinking in major depression

Maria Luca,1 Antonina Luca,2 Carmela Calandra11Department of Medical and Surgery Specialties, Psychiatry Unit of the University Hospital “Policlinico-Vittorio Emanuele” of Catania (Sicily), Italy; 2Department of Neuroscience of the University Hospital “Policlinico-Vitto...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luca M, Luca A, Calandra C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/584e4e98ce8d49f794627ad47e197d51
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Desvenlafaxine in the treatment of major depressive disorder
por: Maria Teresa C Lourenco1, et al.
Publicado: (2009)

Psychomotor approach in children affected by nonretentive fecal soiling (FNRFS): a new rehabilitative purpose
por: Esposito M, et al.
Publicado: (2013)

Nothing to smile about
por: Luca M, et al.
Publicado: (2014)

Psychiatric comorbidities in patients with major depressive disorder
por: Thaipisuttikul P, et al.
Publicado: (2014)

Transcranial magnetic stimulation for the treatment of major depression
por: Janicak PG, et al.
Publicado: (2015)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
por: Dannehl K, et al.
Publicado: (2014)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Mazen K Ali, et al.
Publicado: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
por: Tobe EH
Publicado: (2013)

The cortisol awakening response and major depression: examining the evidence
por: Dedovic K, et al.
Publicado: (2015)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis GA, et al.
Publicado: (2015)

Is placebo useful in the treatment of major depression in clinical practice?
por: Marchesi C, et al.
Publicado: (2013)

Major depressive disorder: mechanism-based prescribing for personalized medicine
por: Saltiel PF, et al.
Publicado: (2015)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
por: Yang X, et al.
Publicado: (2015)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak J, et al.
Publicado: (2013)

A meta-analysis of lipid peroxidation markers in major depression
por: Mazereeuw G, et al.
Publicado: (2015)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang XF, et al.
Publicado: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez E, et al.
Publicado: (2014)

Epidemiology and treatment of mood disorders in a day hospital setting from 1996 to 2007: an Italian study
por: Luca M, et al.
Publicado: (2013)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
por: Marty Hinz, et al.
Publicado: (2010)

Clinical features and imaging findings in a case of Capgras syndrome
por: Luca M, et al.
Publicado: (2013)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
por: Armaly Z, et al.
Publicado: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
por: Bojana Perovic, et al.
Publicado: (2010)

Age-associated decrease in global DNA methylation in patients with major depression
por: Tseng PT, et al.
Publicado: (2014)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
por: Pecenak J, et al.
Publicado: (2013)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
por: Kamijima K, et al.
Publicado: (2013)

Recurrent major depression, ataxia, and cardiomyopathy: association with a novel POLG mutation?
por: Verhoeven WMA, et al.
Publicado: (2011)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
por: Baskaran A, et al.
Publicado: (2013)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
por: Wu MK, et al.
Publicado: (2015)

Differential clinical effects of fluvoxamine by the effect of age in Japanese female major depressive patients
por: Hisashi Higuchi, et al.
Publicado: (2009)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
por: Kamijima K, et al.
Publicado: (2013)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
por: Demir S, et al.
Publicado: (2015)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Bernhard T Baune
Publicado: (2008)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
por: Aoki A, et al.
Publicado: (2014)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
por: Gabriel A
Publicado: (2013)

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
por: Kitaichi Y, et al.
Publicado: (2013)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh M, et al.
Publicado: (2012)

Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients
por: Fornaro M, et al.
Publicado: (2011)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman R, et al.
Publicado: (2011)

Trazodone effects on [3H]-paroxetine and &alpha;2-adrenoreceptors in platelets of patients with major depression
por: Donatella Marazziti, et al.
Publicado: (2010)